In recent years, there has been increased interest in the development of prophylactic and diagnostic tools for patients at high risk for invasive aspergillosis (IA), resulting in a signifi cant investment of human, technical, and economic resources. There are several classic risk factors for the development of IA, including neutropenia, graft-versus-host disease, and corticosteroid use. However, despite having similar risk profi les, only a subset of at-risk individuals will develop this fungal complication. At present, there is a signifi cant expansion of the classically defi ned ‘ high-risk ’ group due to the ageing of the general population, the intensifi cation of treatment strategies, and the introduction of new drugs into clinical practice (e.g., monoclonal antibodies, TNF inhibitors). Therefore, an improved categorization of patients would be useful in order to better target available resources and avoid the risk of potential overtreatment and toxicities.
Caira, M., Mancinelli, M., Leone, G., Pagano, L., Invasive aspergillosis in acute leukemias: old and new risk factors and epidemiological trends, <<MEDICAL MYCOLOGY>>, 2011; 49 Suppl 1 (49): S13-S13-6. [doi:10.3109/13693786.2010.509138] [http://hdl.handle.net/10807/3791]
Invasive aspergillosis in acute leukemias: old and new risk factors and epidemiological trends
Caira, Morena;Leone, Giuseppe;Pagano, Livio
2011
Abstract
In recent years, there has been increased interest in the development of prophylactic and diagnostic tools for patients at high risk for invasive aspergillosis (IA), resulting in a signifi cant investment of human, technical, and economic resources. There are several classic risk factors for the development of IA, including neutropenia, graft-versus-host disease, and corticosteroid use. However, despite having similar risk profi les, only a subset of at-risk individuals will develop this fungal complication. At present, there is a signifi cant expansion of the classically defi ned ‘ high-risk ’ group due to the ageing of the general population, the intensifi cation of treatment strategies, and the introduction of new drugs into clinical practice (e.g., monoclonal antibodies, TNF inhibitors). Therefore, an improved categorization of patients would be useful in order to better target available resources and avoid the risk of potential overtreatment and toxicities.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.